Israel - Ibrani - Ministry of Health

טי. סי. טכנוקר מוצרי בריאות בע"מ - כלל האוכלוסיה - טיפול המסייע בתהליכי תיקון במצבי אטרופיה ודיסטרופיה של הרקמה הווגינאלית. טיפול זה מזרז החלמה לאחר לידה, במקרים של ניתוח גניקולוגי, במקרים של דיסטרופיה כתוצאה מכימותרפיה, קרינה מייננת או יובש וגינאלי וגם כתוצאה מהעדר אסטרוגן.

Israel - Ibrani - Ministry of Health

abic ltd. - omeprazole 10.0 mg - capsules - omeprazole - - acute duodenal ulcer. - acute gastric ulcer. - helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. - reflux esophagitis:• treatment;• long-term management;• maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. - severe reflux esophagitis in children from one year of age and older • maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer.• zollinger-ellison syndrome.• treatment and prevention of nsaid – associated duodenal and gastric ulcers or erosions in high risk patients.

Israel - Ibrani - Ministry of Health

abic ltd. - omeprazole 10.0 mg - capsules - omeprazole - - acute duodenal ulcer. - acute gastric ulcer. - helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. - reflux esophagitis:• treatment;• long-term management;• maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. - severe reflux esophagitis in children from one year of age and older • maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer.• zollinger-ellison syndrome.• treatment and prevention of nsaid – associated duodenal and gastric ulcers or erosions in high risk patients.

Israel - Ibrani - Ministry of Health

rafa laboratories ltd - omeprazole 10 mg - capsules - omeprazole - acute duodenal ulcer, acute gastric ulcer, helicobacter pylori associated peptic ulcer disease in combination with antibiotics. reflux esophagitis: treatment long-term management, maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. treatment of severe reflux esophagitis in children from one year of age and older. maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. zollinger-ellison syndrome. treatment and prevention of nsaid-associated duodenal and gastric ulcer or erosions in high risk patients.

Israel - Ibrani - Ministry of Health

glaxo smith kline (israel) ltd - orlistat 60 mg - capsules - orlistat - for weight loss in overweight adults, 18 years and older, when used along with a reduced - calorie and low-fat diet.

Israel - Ibrani - Ministry of Health

teva pharmaceutical indust.ltd - alfacalcidol 0.5 mcg - capsules - alfacalcidol - renal bone disease . hypoparathyroidisim. rickets and osteomalacia. osteoporosis. primary and tertiary hyperparathyroidism. neonatal hypocalcemia.

Israel - Ibrani - Ministry of Health

rafa laboratories ltd - acetylsalicylic acid 25 mg; dipyridamole 200 mg - capsules - acetylsalicylic acid - secondary prevention of ischaemic strokes and transient ischaemic attacks (tia).

Israel - Ibrani - Ministry of Health

glaxo smith kline (israel) ltd - isosorbide-5-mononitrate 50 mg - capsules - isosorbide mononitrate - for the prophylaxis of angina pectoris.

Israel - Ibrani - Ministry of Health

nutrition consumer health - monoxerutin 300 mg - capsules - monoxerutin - for the adjunctive treatment of varicose veins in all stages.

Israel - Ibrani - Ministry of Health

rafa laboratories ltd - ramipril 2.5 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.